Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015, Article ID 517472, 7 pages
Clinical Study

Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes

1Kagawa University School of Medicine, Kagawa 761-0793, Japan
2Jichi Medical University School of Medicine, Tochigi, Japan
3Tulane University Health Sciences Center, New Orleans, LA, USA
4Miyazaki University School of Medicine, Miyazaki, Japan

Received 11 November 2014; Revised 1 February 2015; Accepted 9 February 2015

Academic Editor: Bagher Larijani

Copyright © 2015 Tomoko Mizushige et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. The aims of this study were (1) to examine the renoprotective effects of alogliptin and (2) to establish urinary angiotensinogen (AGT) as a prognostic marker of renoprotective effects of alogliptin in patients with type 2 diabetes (T2D). Methods. In 43 patients with T2D (18 women, years), 25 mg/day of alogliptin was added to the traditional hypoglycemic agents and/or nondrug treatments. Urinary concentrations of albumin (Alb) and AGT, normalized by urinary concentrations of creatinine (Cr) (UAlbCR and UAGTCR, respectively), were measured before and after the 12-week alogliptin treatment. Results. Alogliptin treatment tended to decrease UAlbCR ( versus  mg/g Cr, ). Based on % change in UAlbCR, patients were divided into two groups, responders () and nonresponders (), and a logistic analysis of UAGTCR before treatment showed cutoff value of 20.8 µg/g Cr. When all patients were redivided into two groups, those with higher values of UAGTCR before the treatment (Group H, ) and those with lower values (Group L), Group H showed significantly decreased UAlbCR in response to alogliptin ( versus , ). Conclusion. Urinary AGT could be a prognostic marker of renoprotective effects of alogliptin in patients with T2D.